The Cooper Health System
Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medicine before radiation works well. After radiation, MRI scans can be harder to understand because radiation changes how the brain looks on the scan. If new medicines are given before radiation, the scans are easier to read. First, the investigators need to find out if giving chemotherapy early works using a drug we already know can treat gliomas. The investigators will start with temozolomide, which is the only chemotherapy approved by the FDA for HGG. If this approach is successful, the investigators can then test new drugs using this screening method.
Inclusion Criteria: 1. Pathologic diagnosis of high-grade glioma 2. Residual measurable post-operative contrast enhancing tumor 3. Lack of urgency in requiring immediate radiation or chemotherapy (mass effect, mid-line shift, herniation, etc.) 4. Ability to provide informed consent 5. Willingness to comply with all study procedures and availability for the duration of the study 6. Male or female, aged 18-80. 7. Karnofsky Performance Status ³70%. 8. Patients must have the following organ and marrow functions: Absolute neutrophil count ≥1,500/µL Platelets ≥100,000/µL Hemoglobin ≥ 9 g/dL Tot…
Patients will receive 2 cycles of pre-radiation temozolomide (200mg/m\^2). Cycles are 28-days in length. Participants will take temozolomide on days 1-5 of the 28-day cycle.
Arctuva estimate
Verify or correct the compensation shown for this listing.